It seems it's now official. Lilly has effectively levied a fat tax on Canadian prescriptions of its diabetes and obesity medication tirzepatide (aka Mounjaro/Zepbound) whereby if prescribed for obesity, you'll pay nearly double what you'd pay if prescribed for diabetes. More in my Substack